Pharmacologically Assisted Treatment of Opioid-Dependent Youth
- 303 Downloads
Opioid misuse, abuse, and dependence are global problems whose patterns vary across cultures. In the USA, the non-medical use of prescription opioids has become particularly serious because of its association with addiction and overdose death. Agonist and antagonist medications have been shown to be effective for opioid-dependent adults, and there is a growing body of data that they are also effective for youth. Here, we summarize evidence that detoxification alone results in high rates of treatment dropout and relapse but that the limited but growing data on the extended use of medication-assisted treatment for opioid-dependent youth have been positive. The implementation of medication-assisted treatment as a standard practice is feasible, easily integrated with counseling or psychotherapy, and has potential to greatly improve outcomes. Although concerns about safety and efficacy with youth require more research, and we do not advocate indefinite maintenance, we suggest that opioid-dependent youth should be considered as candidates for medication-assisted treatment delivered in a comprehensive, developmentally appropriate context, beginning at the first episode of care, with the strength of the recommendation to use medication increasing with each care episode.
KeywordsHeroin Buprenorphine Naltrexone Opioid Dependence Prescription Opioid
No funding sources were used to prepare this article, but MF is a member of the Clinical Advisory Board for Orexo, which manufactures a buprenorphine product for which it is seeking FDA approval. MF has an equity interest in a community treatment provider (Maryland Treatment Centers) at which youth opioid treatment is delivered, including medications. GW and AP received salary support from NIDA U10 DA-13043, and GW received salary support from NIDA KO5 DA-17009. GW was the principal investigator of a Clinical Trials Network (CTN) study on buprenorphine among adolescents in which the medication was supplied by Reckitt-Benckiser, and Alkermes has provided XR-NTX for a study in which he is a co-investigator. MF received salary support from NIDA R01 DA02455301, NIDA-VA CS #1030, and NIDA-VA CS #1031. MF participated in a CTN study on buprenorphine among adolescents in which the medication was supplied by Reckitt-Benckiser, and Alkermes has provided XR-NTX for a study in which he is a co-investigator. GP is a co-investigator of a study of Suboxone® and methadone for HIV risk reduction, funded by National Institute on Drug Abuse grants R21-DA-026754, U10 DA-13043, and KO5 DA-17009. Reckitt Benckiser supplied Suboxone® for the trial. MM and AP report no conflicts of interest.
- 1.UNODC. World drug report 2011. Geneva. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2011.html.
- 3.Johnston LD, O’Malley PM, Bachman JG, et al. Monitoring the future: national survey results on drug use, 1975–2010. Bethesda: National Institute on Drug Abuse; 2009.Google Scholar
- 4.Johnston LD, O’Malley PM, Bachman JG, et al. Monitoring the future national survey results on drug use, 1975–2005: vol 1, secondary students (NIH publication no. 06-5883). Bethesda: National Institute on Drug Abuse; 2006.Google Scholar
- 5.SAMHSA. The NSDUH report: patterns and trends in nonmedical prescription pain reliever use: 2002–2005. Rockville: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2007.Google Scholar
- 6.SAMHSA. Results from the 2006 national survey on drug use and health: national findings. Rockville: SAMHSA; 2007.Google Scholar
- 7.Epstein DH, Phillips KA, Preston KL. Opioids. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins Health; 2011. p. 161–90.Google Scholar
- 8.Hasin D, Nunes E, Meydan J. Comorbidity of alcohol, drug and psychiatric disorders: epidemiology. In: Kranzler HR, Tinsley JA, editors. Dual diagnosis and psychiatric treatment: substance abuse and comorbid disorders. New York: Marcel Dekker Inc.; 2004. p. 1–33.Google Scholar
- 16.Pecoraro A, Woody GE. Medication-assisted treatment for opioid dependence: making a difference in prisons. F1000 Med Rep. 2011;3:1.Google Scholar
- 17.WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 2009. http://www.who.int/substanceabuse/publications/opioiddependenceguidelines.pdf.
- 18.Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS): 2010. Admissions. Rockville: Substance Abuse and Mental Health Services Administration; 2010.Google Scholar
- 21.Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescents. Cochrane Database Syst Rev. 2009;2:CD007210.Google Scholar
- 22.Lehmann WX. The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. NIDA Monograph. 1973;8:82–3.Google Scholar
- 25.Minozzi S, Amato L, Davoli M. Detoxification treatments for opiate dependent adolescents. Cochrane Database Syst Rev. 2009;2:CD006749.Google Scholar
- 27.Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005;(3):CD003409.Google Scholar
- 28.Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.Google Scholar
- 36.Reckitt Benkiser. Further US RB Pharmaceuticals announcement. 2012 [cited 2012 October 1]. http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pageid=1332&cc=GB.
- 41.Resnick RB, editor. A practitioner’s experience with naltrexone. In: Proceedings of the 29th annual scientific conference of the American Society of Addiction Medicine; 1998; New OrleansGoogle Scholar
- 47.Department of Health. Guidance for the pharmacological management of substance misuse among young people. London: Department of Health; 2009 http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_106429.pdf.
- 48.College of Physicians and Surgeons of Ontario. Methadone maintenance guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2005.Google Scholar
- 49.College of Physicians and Surgeons of Ontario. Methadone maintenance guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2011 http://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf.
- 50.Code of Federal Regulations, Title 42, section 8. Conditions for distribution and use of methadone products for the treatment of opioid addiction. http://www.dpt.samhsa.gov/regulations/legreg.aspx.
- 51.Drug Addiction Treatment Act of 2000. Title XXXV, section 3502 of the Children’s Health Act of 2000. AKA PL 106-310. http://buprenorphine.samhsa.gov/fulllaw.html.
- 53.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.Google Scholar
- 54.Reckitt-Benkiser. Letter to prescribers of Suboxone® tablets.Google Scholar
- 55.Saxon AJ, Miotto K. Methadone maintenance. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott & Williams Wilkins; 2011. p. 419–36.Google Scholar
- 56.Methadone hydrochloride Intensol™ (Oral concentrate, USP) prescribing information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0e6a966-179a-45e0-8444-4c1b8523f8d2.
- 57.Tompkins DA, Strain EC. Buprenorphine in the treatment of opioid dependence. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott & Williams Wilkins; 2011. p. 437–56.Google Scholar
- 58.Suboxone Sublingual Film® prescribing information. http://www.suboxone.com/pdfs/SuboxonePI.pdf.
- 59.Harrison E, Petrakis I. Naltrexone pharmacotherapy. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Lippincott Williams & Wilkins: Philadelphia; 2011. p. 447–65.Google Scholar
- 60.Vivitrol® (naltrexone for extended release injectable suspension) prescribing information. http://www.vivitrol.com/Content/pdf/prescribing_info.pdf.